|
000
| 02165nam 2200433zi 4500 |
|---|
| 001 | 9.916203 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221207160706 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 221014e20221021onc ob f000 0 eng d |
|---|
| 020 | |a9780660458274 |q(report) |
|---|
| 020 | |a9780660458281 |q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-144/1-2022E-PDF |
|---|
| 086 | 1 |aHP5-144/2-2022E-PDF |
|---|
| 245 | 00|aRecommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cOctober 21, 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (27 pages) + |esummary (6 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations sur l'utilisation du vaccin Comirnaty (3 mcg) de Pfizer-BioNTech contre la COVID-19 chez les enfants de 6 mois à 4 ans. |
|---|
| 500 | |aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 220481." |
|---|
| 500 | |a"Pub.: 220483." |
|---|
| 504 | |aIncludes bibliographical references (pages 21-23). |
|---|
| 650 | 0|aCOVID-19 vaccines|zCanada. |
|---|
| 650 | 0|aVaccination of children|zCanada. |
|---|
| 650 | 0|aCOVID-19 vaccines|xGovernment policy|zCanada. |
|---|
| 650 | 0|aVaccination of children|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRecommandations sur l'utilisation du vaccin Comirnaty (3 mcg) de Pfizer-BioNTech contre la COVID-19 chez les enfants de 6 mois à 4 ans.|w(CaOODSP)9.916206 |
|---|
| 856 | 40|qPDF|s1.88 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-144-1-2022-eng.pdf|z(report) |
|---|
| 856 | 40|qPDF|s1.13 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-144-2-2022-eng.pdf|z(summary) |
|---|